Lyra Therapeutics (LYRA) Total Current Liabilities (2019 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Total Current Liabilities of $9.5 million in Q4 2025, little changed on a QoQ basis from $9.5 million in Q3 2025, and down 24.61% YoY from $12.6 million in Q4 2024.
Lyra Therapeutics (LYRA) Total Current Liabilities (2019 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Total Current Liabilities for 7 consecutive years, with $9.5 million the latest figure, recorded in Q4 2025.
- Total Current Liabilities for Q4 2025 came in at $9.5 million, down 24.61% year-over-year; the trailing twelve-month figure through Dec 2025 was $9.5 million (down 24.61% YoY), and the FY2025 annual result was $9.5 million, down 24.61% from the prior year.
- Total Current Liabilities for Q4 2025 stood at $9.5 million, roughly flat from $9.5 million in the prior quarter.
- The five-year high for Total Current Liabilities was $22.0 million in Q1 2022, with the low at $4.2 million in Q1 2021.
- A 5-year average of $14.1 million and a median of $14.1 million in 2023 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities surged 426.74% in 2022 and slumped 42.09% in 2025, its largest moves.
- Lyra Therapeutics' Total Current Liabilities stood at $18.2 million in 2021, then retreated by 20.69% to $14.5 million in 2022, then surged by 35.43% to $19.6 million in 2023, then sank by 35.55% to $12.6 million in 2024, then declined by 24.61% to $9.5 million in 2025.
- The last three Total Current Liabilities figures came in at $9.5 million (Q4 2025), $9.5 million (Q3 2025), and $11.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | 9.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.52 Mn |
| Sep 30, 2025 | 9.48 Mn |
| Jun 30, 2025 | 11.16 Mn |
| Mar 31, 2025 | 11.47 Mn |
| Dec 31, 2024 | 12.63 Mn |
| Sep 30, 2024 | 14.95 Mn |
| Jun 30, 2024 | 19.28 Mn |
| Mar 31, 2024 | 18.72 Mn |
| Dec 31, 2023 | 19.60 Mn |
| Sep 30, 2023 | 19.24 Mn |
| Jun 30, 2023 | 14.11 Mn |
| Mar 31, 2023 | 14.15 Mn |
| Dec 31, 2022 | 14.47 Mn |
| Sep 30, 2022 | 13.61 Mn |
| Jun 30, 2022 | 10.61 Mn |
| Mar 31, 2022 | 21.97 Mn |
| Dec 31, 2021 | 18.25 Mn |
| Sep 30, 2021 | 17.77 Mn |
| Jun 30, 2021 | 5.90 Mn |
| Mar 31, 2021 | 4.17 Mn |